Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Monday, November 11, 2019
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Medical devices, Life sciences, Articles, Biotechnology, Pharmaceutical industry, Dermatology, Biopharmaceutical
Geotags: 
California, NEW YORK, United States
⚠ generated by AI ↴
Organisation: 
DERMIRA
Summary
Key Points: 
  • Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions.
  • Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.
  • Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com .
  • Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD.


Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day on Monday, November 18, 2019 at 9:00 a.m. ET in New York, NY.

A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.

About Dermira

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products. The company’s approved treatment, QBREXZA® (glycopyrronium) cloth, is indicated for pediatric and adult patients (ages 9 and older) with primary axillary hyperhidrosis (excessive underarm sweating). Please see the QBREXZA prescribing information. Dermira is evaluating lebrikizumab in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis (a severe form of eczema) and has early-stage research and development programs in other areas of dermatology. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow Dermira on Twitter, LinkedIn and Instagram.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc-), corporate Instagram account (https://www.instagram.com/dermira_inc/) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page, Instagram and Twitter accounts in addition to following its SEC filings, news releases, public conference calls and webcasts.

Copyright: 
Copyright Business Wire 2019